Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force.

Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force.

A Task Force was commissioned collectively by the European Academy of Allergy and Clinical Immunology (EAACI) and the Respiratory Effectiveness Group (REG) to develop a high quality evaluation device for real-life observational analysis to establish high-quality real-life bronchial asthma research that might be thought-about inside future guideline growth.The ensuing REal Life EVidence AssessmeNt Tool (RELEVANT) was achieved by way of an intensive evaluation of present initiatives in this space.

The first model was piloted amongst 9 raters throughout 6 articles; the revised, interim, model underwent in depth testing by 22 reviewers from the EAACI membership and REG collaborator group, resulting in additional revisions and device finalisation. RELEVANT was validated by way of an evaluation of real-life effectiveness research recognized by way of systematic evaluate of Medline and Embase databases and regarding subjects for which real-life research might provide priceless proof complementary to that from randomised managed trials.

The subjects have been chosen by way of a vote amongst Task Force members and associated to the affect of adherence, smoking, inhaler machine and particle measurement on bronchial asthma remedy effectiveness.Although highlighting a basic lack of high-quality real-life effectiveness observational analysis on these clinically vital subjects, the evaluation offered insights into how recognized observational research may inform bronchial asthma pointers builders and clinicians.

Overall, RELEVANT appeared dependable and straightforward to make use of by professional reviewers.Using such high quality appraisal instruments is obligatory to evaluate whether or not particular observational real-life effectiveness research can be utilized to tell guideline growth and/or decision-making in medical observe.

 Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force.
Quality standards in respiratory real-life effectiveness analysis: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force.

New European Academy of Allergy and Clinical Immunology definition on pollen season mirrors symptom load for grass and birch pollen-induced allergic rhinitis.

BACKGROUND
The use of allergen immunotherapy (AIT) for allergic rhinitis and its medical efficacy in medical trials will depend on the efficient dedication of pollen allergen publicity time durations. We consider pollen information from Germany to look at the new definitions on pollen season and peak pollen interval begin and finish as proposed by the European Academy of Allergy and Clinical Immunology (EAACI) in a just lately printed Position Paper. The goal was to reveal the potential of these definitions to reflect symptom hundreds for grass and birch pollen-induced allergic rhinitis primarily based on real-life information.

FBXW7 siRNA

20-abx916668
  • Ask for price
  • Ask for price
  • 15 nmol
  • 30 nmol

FBXW7 siRNA

20-abx916669
  • Ask for price
  • Ask for price
  • 15 nmol
  • 30 nmol

FBXW7 Antibody

1-CSB-PA623964
  • Ask for price
  • Ask for price
  • 100ul
  • 50ul
Description: A polyclonal antibody against FBXW7. Recognizes FBXW7 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200

FBXW7 Antibody

E036334 100μg/100μl
EUR 255
Description: Available in various conjugation types.

FBXW7 Antibody

E95872 100ul
EUR 255
Description: Available in various conjugation types.

FBXW7 Antibody

F53267-0.08ML 0.08 ml
EUR 140.25
Description: Substrate recognition component of an SCF (SKP1-CUL1-F- box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes and binds phosphorylated sites/phosphodegrons within target proteins and thereafter bring them to the SCF complex for ubiquitination. Identified substrates include cyclin-E, MYC, NOTCH1 released notch intracellular domain (NICD), and probably PSEN1. [UniProt]

FBXW7 Antibody

F53267-0.4ML 0.4 ml
EUR 322.15
Description: Substrate recognition component of an SCF (SKP1-CUL1-F- box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes and binds phosphorylated sites/phosphodegrons within target proteins and thereafter bring them to the SCF complex for ubiquitination. Identified substrates include cyclin-E, MYC, NOTCH1 released notch intracellular domain (NICD), and probably PSEN1. [UniProt]

FBXW7 Antibody

F53304-0.08ML 0.08 ml
EUR 140.25
Description: Substrate recognition component of an SCF (SKP1-CUL1-F- box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes and binds phosphorylated sites/phosphodegrons within target proteins and thereafter bring them to the SCF complex for ubiquitination. Identified substrates include cyclin-E, MYC, NOTCH1 released notch intracellular domain (NICD), and probably PSEN1. [UniProt]

FBXW7 Antibody

F53304-0.4ML 0.4 ml
EUR 322.15
Description: Substrate recognition component of an SCF (SKP1-CUL1-F- box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes and binds phosphorylated sites/phosphodegrons within target proteins and thereafter bring them to the SCF complex for ubiquitination. Identified substrates include cyclin-E, MYC, NOTCH1 released notch intracellular domain (NICD), and probably PSEN1. [UniProt]

FBXW7 Antibody

DF12400 200ul
EUR 420

FBXW7 Antibody

DF12400-100ul 100ul
EUR 280

FBXW7 Antibody

DF12400-200ul 200ul
EUR 350

FBXW7 antibody

E39-03057 100ug/100ul
EUR 225
Description: Available in various conjugation types.

FBXW7 Antibody

E309184 200ul
EUR 275
Description: Available in various conjugation types.

FBXW7 Antibody

36334 100ul
EUR 319

FBXW7 Antibody

36334-100ul 100ul
EUR 302.4

FBXW7 antibody

70R-6541 50 ug
EUR 467
Description: Rabbit polyclonal FBXW7 antibody raised against the C terminal of FBXW7

FBXW7 Antibody

1-CSB-PA251991
  • Ask for price
  • Ask for price
  • 100ul
  • 50ul
Description: A polyclonal antibody against FBXW7. Recognizes FBXW7 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:10000, IHC:1:100-1:300

FBXW7 Antibody

1-CSB-PA822163LA01HU
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against FBXW7. Recognizes FBXW7 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200

Fbxw7 Antibody

GWB-MM538G 50ug Ask for price

FBXW7 Antibody

GWB-MQ768C 50ug Ask for price

FBXW7 Rabbit pAb

E2505872 100ul
EUR 225
Description: Available in various conjugation types.

FBXW7 Rabbit pAb

A5872-100ul 100 ul
EUR 369.6

FBXW7 Rabbit pAb

A5872-200ul 200 ul
EUR 550.8

FBXW7 Rabbit pAb

A5872-20ul 20 ul
EUR 219.6

FBXW7 Rabbit pAb

A5872-50ul 50 ul
EUR 267.6

anti- FBXW7 antibody

FNab03057 100µg
EUR 702
Description: Antibody raised against FBXW7

FBXW7 cloning plasmid

CSB-CL822163HU-10ug 10ug
EUR 846
Description: A cloning plasmid for the FBXW7 gene.

FBXW7 Blocking Peptide

33R-5108 100 ug
EUR 119
Description: A synthetic peptide for use as a blocking control in assays to test for specificity of FBXW7 antibody, catalog no. 70R-6541

FBXW7 Blocking Peptide

DF12400-BP 1mg
EUR 234

FBXW7 Polyclonal Antibody

E-AB-68384-120uL 120uL
EUR 320
Description: Unconjugated

FBXW7 Polyclonal Antibody

E-AB-68384-200uL 200uL
EUR 530
Description: Unconjugated

FBXW7 Polyclonal Antibody

E-AB-68384-60uL 60uL
EUR 200
Description: Unconjugated

FBXW7 Polyclonal Antibody

E-AB-68384-each each Ask for price
Description: Unconjugated

FBXW7 Polyclonal Antibody

E-AB-14856-120uL 120uL
EUR 240
Description: Unconjugated

FBXW7 Polyclonal Antibody

E-AB-14856-200uL 200uL
EUR 399
Description: Unconjugated

FBXW7 Polyclonal Antibody

E-AB-14856-20uL 20uL
EUR 73
Description: Unconjugated

FBXW7 Polyclonal Antibody

E-AB-14856-60uL 60uL
EUR 143
Description: Unconjugated

FBXW7 Polyclonal Antibody

E-AB-11064-120uL 120uL
EUR 240
Description: Unconjugated

FBXW7 Polyclonal Antibody

E-AB-11064-200uL 200uL
EUR 399
Description: Unconjugated

FBXW7 Polyclonal Antibody

E-AB-11064-20uL 20uL
EUR 73
Description: Unconjugated

FBXW7 Polyclonal Antibody

E-AB-11064-60uL 60uL
EUR 143
Description: Unconjugated

pECMV- 3*Flag- FBXW7

PVT10356 2 ug
EUR 361.2

FBXW7 ELISA KIT|Human

EF009598 96 Tests
EUR 826.8

Human FBXW7 shRNA Plasmid

20-abx960632
  • Ask for price
  • Ask for price
  • 150 µg
  • 300 µg

Mouse FBXW7 shRNA Plasmid

20-abx974100
  • Ask for price
  • Ask for price
  • 150 µg
  • 300 µg

FBXW7 Antibody, HRP conjugated

1-CSB-PA822163LB01HU
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against FBXW7. Recognizes FBXW7 from Human. This antibody is HRP conjugated. Tested in the following application: ELISA

FBXW7 Antibody, FITC conjugated

1-CSB-PA822163LC01HU
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against FBXW7. Recognizes FBXW7 from Human. This antibody is FITC conjugated. Tested in the following application: ELISA

OEEG01153-50UG - FBXW7 Peptide

OEEG01153-50UG 50ug
EUR 189

FBXW7 Recombinant Protein (Mouse)

RP134159 100 ug Ask for price

FBXW7 Recombinant Protein (Mouse)

RP134162 100 ug Ask for price

FBXW7 Recombinant Protein (Mouse)

RP134165 100 ug Ask for price

FBXW7 Recombinant Protein (Human)

RP039052 100 ug Ask for price

FBXW7 Rabbit Polyclonal Antibody

54933 100ul
EUR 439

FBXW7 Antibody, Biotin conjugated

1-CSB-PA822163LD01HU
  • Ask for price
  • Ask for price
  • 100ug
  • 50ug
Description: A polyclonal antibody against FBXW7. Recognizes FBXW7 from Human. This antibody is Biotin conjugated. Tested in the following application: ELISA

FBXW7 Rabbit Polyclonal Antibody

E10G08139 100 μl
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

FBXW7 Rabbit Polyclonal Antibody

E10G01193 100 μl
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

FBXW7 (N-term) Rabbit pAb

E2618883 100ul
EUR 225
Description: Available in various conjugation types.

FBXW7 (N-term) Rabbit pAb

E2618918 100ul
EUR 225
Description: Available in various conjugation types.

FBXW7 ORF Vector (Human) (pORF)

ORF013018 1.0 ug DNA
EUR 114

Fbxw7 ORF Vector (Mouse) (pORF)

ORF044721 1.0 ug DNA
EUR 607.2

Fbxw7 ORF Vector (Mouse) (pORF)

ORF044722 1.0 ug DNA
EUR 607.2

Fbxw7 ORF Vector (Mouse) (pORF)

ORF044723 1.0 ug DNA
EUR 607.2

Human FBXW7 (-/-) HCT116 Cell Line

ABC-KD5439 1 vial Ask for price
Description: Human FBXW7 (-/-) HCT116 Cell line is Homozygous knockdown of FBXW7 exon 5 which encodes F-box domain of the protein

Human FBXW7 (-/-) HCT116 Cell Line

ABC-KH5439 1 vial Ask for price
Description: Human FBXW7 (-/-) HCT116 Cell line is Homozygous knockout of FBXW7 exon 5 which encodes F-box domain of the protein

Human FBXW7 knockout cell line

ABC-KH5437 1 vial Ask for price
Description: Human FBXW7 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology.

Human FBXW7 knockdown cell line

ABC-KD5437 1 vial Ask for price
Description: Human FBXW7 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest.

Human FBXW7 Protein Lysate 20ug

IHUFBXW7PLLY20UG each
EUR 361
Description: Human FBXW7 Protein Lysate 20ug

OCOA16387-20UG - FBXW7 Protein Lysate

OCOA16387-20UG 20ug
EUR 269

OCOA09627-20UG - FBXW7 Protein Lysate

OCOA09627-20UG 20ug
EUR 269

OCOA02954-20UG - FBXW7 Protein Lysate

OCOA02954-20UG 20ug
EUR 269

FBXW7 Over-expression Lysate Product

GWB-856163 0.1 mg Ask for price

FBXW7 Over-expression Lysate Product

GWB-734490 0.1 mg Ask for price

Human FBXW7 (-/-) DLD-1 Cell Line

ABC-KD5438 1 vial Ask for price
Description: Human FBXW7 (-/-) DLD-1 Cell line is Homozygous knockdown of FBXW7 exon 5 which encodes F-box domain of the protein

Human FBXW7 (+/-) DLD-1 Cell Line

ABC-KD5440 1 vial Ask for price
Description: Human FBXW7 (+/-) DLD-1 Cell line is Heterozygous knockdown of FBXW7 exon 5 which encodes F-box domain of the protein

Human FBXW7 (-/-) DLD-1 Cell Line

ABC-KH5438 1 vial Ask for price
Description: Human FBXW7 (-/-) DLD-1 Cell line is Homozygous knockout of FBXW7 exon 5 which encodes F-box domain of the protein

Human FBXW7 (+/-) DLD-1 Cell Line

ABC-KH5440 1 vial Ask for price
Description: Human FBXW7 (+/-) DLD-1 Cell line is Heterozygous knockout of FBXW7 exon 5 which encodes F-box domain of the protein

Polyclonal Fbxw7 antibody - middle region

APR00709G 0.05mg
EUR 633.6
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human Fbxw7 - middle region. This antibody is tested and proven to work in the following applications:

FBXW7 (untagged)-Human F-box and WD repeat domain containing 7 (FBXW7), transcript variant 2

SC113537 10 µg Ask for price

FBXW7 (untagged)-Human F-box and WD repeat domain containing 7 (FBXW7), transcript variant 1

SC110514 10 µg Ask for price

FBXW7 (untagged)-Human F-box and WD repeat domain containing 7 (FBXW7), transcript variant 3

SC301782 10 µg Ask for price

FBXW7 rabbit polyclonal antibody, Purified

AP05288SU-N 100 µg Ask for price

OPCD03137-10UG - FBXW7 Recombinant Protein

OPCD03137-10UG 10ug
EUR 139

OPCD03137-50UG - FBXW7 Recombinant Protein

OPCD03137-50UG 50ug
EUR 349

OPCD03138-10UG - FBXW7 Recombinant Protein

OPCD03138-10UG 10ug
EUR 149

OPCD03138-50UG - FBXW7 Recombinant Protein

OPCD03138-50UG 50ug
EUR 379

OPCD03137-200UG - FBXW7 Recombinant Protein

OPCD03137-200UG 200ug
EUR 699

OPCD03138-200UG - FBXW7 Recombinant Protein

OPCD03138-200UG 200ug
EUR 749

Fbxw7 (untagged) - Mouse F-box and WD-40 domain protein 7 (Fbxw7), transcript variant 3, (10ug)

MC219910 10 µg Ask for price

Fbxw7 (untagged) - Mouse F-box and WD-40 domain protein 7 (Fbxw7), transcript variant 2, (10ug)

MC220782 10 µg Ask for price

Fbxw7 (untagged) - Mouse F-box and WD-40 domain protein 7 (Fbxw7), transcript variant 1, (10ug)

MC220783 10 µg Ask for price

FBXW7 (GFP-tagged) - Human F-box and WD repeat domain containing 7 (FBXW7), transcript variant 1

RG217398 10 µg Ask for price

FBXW7 (GFP-tagged) - Human F-box and WD repeat domain containing 7 (FBXW7), transcript variant 3

RG221116 10 µg Ask for price

FBXW7 (GFP-tagged) - Human F-box and WD repeat domain containing 7 (FBXW7), transcript variant 2

RG223843 10 µg Ask for price

Fbxw7 sgRNA CRISPR Lentivector set (Mouse)

K4531701 3 x 1.0 ug
EUR 406.8

FBXW7 / FBW7 Mouse Monoclonal (3D1) Antibody

TA316739 50 µg Ask for price

FBXW7 sgRNA CRISPR Lentivector set (Human)

K0767601 3 x 1.0 ug
EUR 406.8

Fbxw7 (GFP-tagged) - Mouse F-box and WD-40 domain protein 7 (Fbxw7) transcript variant 2, (10ug)

MG225460 10 µg Ask for price

Fbxw7 (GFP-tagged) - Mouse F-box and WD-40 domain protein 7 (Fbxw7) transcript variant 1, (10ug)

MG225461 10 µg Ask for price

Fbxw7 (GFP-tagged) - Mouse F-box and WD-40 domain protein 7 (Fbxw7) transcript variant 3, (10ug)

MG225462 10 µg Ask for price

FBXW7 (N-term) rabbit polyclonal antibody

AP23571PU-N 50 µg Ask for price

FBXW7 (N-term) Rabbit Polyclonal Antibody

E10G33089 100 μl
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

FBXW7 (N-term) Rabbit Polyclonal Antibody

E10G33111 100 μl
EUR 275
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

Fbxw7 3'UTR GFP Stable Cell Line

TU156466 1.0 ml Ask for price

FBXW7 3'UTR GFP Stable Cell Line

TU057813 1.0 ml
EUR 1825.2

Fbxw7 (Myc-DDK-tagged) - Mouse F-box and WD-40 domain protein 7 (Fbxw7), transcript variant 2

MR225460 10 µg Ask for price

Fbxw7 (Myc-DDK-tagged) - Mouse F-box and WD-40 domain protein 7 (Fbxw7), transcript variant 1

MR225461 10 µg Ask for price

Fbxw7 (Myc-DDK-tagged) - Mouse F-box and WD-40 domain protein 7 (Fbxw7), transcript variant 3

MR225462 10 µg Ask for price

Polyclonal FBXW7 / FBW7 Antibody (N-Terminus)

APR02668G 0.05mg
EUR 580.8
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human FBXW7 / FBW7 (N-Terminus). This antibody is tested and proven to work in the following applications:

AAP37443-100UG - Fbxw7 Peptide - middle region

AAP37443-100UG 100ug
EUR 99

FBXW7 (Myc-DDK-tagged)-Human F-box and WD repeat domain containing 7 (FBXW7), transcript variant 3

RC221116 10 µg Ask for price

FBXW7 (Myc-DDK-tagged)-Human F-box and WD repeat domain containing 7 (FBXW7), transcript variant 2

RC223843 10 µg Ask for price

FBXW7 (Myc-DDK-tagged)-Human F-box and WD repeat domain containing 7 (FBXW7), transcript variant 1

RC217398 10 µg Ask for price

FBXW7 rabbit polyclonal antibody, Aff - Purified

AP05288PU-N 100 µg Ask for price

ARP37443_P050-25UL - Fbxw7 Antibody - middle region

ARP37443_P050-25UL 25ul
EUR 99

OPCA05331-20UG - FBXW7 Recombinant Protein (Human)

OPCA05331-20UG 20ug
EUR 863

FBXW7 Protein Vector (Human) (pPM-C-HA)

PV052071 500 ng
EUR 577.2

FBXW7 Protein Vector (Mouse) (pPM-C-HA)

PV178884 500 ng
EUR 1278

FBXW7 Protein Vector (Mouse) (pPM-C-HA)

PV178888 500 ng
EUR 1278

FBXW7 Protein Vector (Mouse) (pPM-C-HA)

PV178892 500 ng
EUR 723.6

OPCA05331-100UG - FBXW7 Recombinant Protein (Human)

OPCA05331-100UG 100ug
EUR 988

FBXW7 Protein Vector (Human) (pPB-C-His)

PV052069 500 ng
EUR 577.2

FBXW7 Protein Vector (Human) (pPB-N-His)

PV052070 500 ng
EUR 577.2

FBXW7 Protein Vector (Human) (pPM-C-His)

PV052072 500 ng
EUR 577.2

FBXW7 Protein Vector (Mouse) (pPB-C-His)

PV178882 500 ng
EUR 1278

FBXW7 Protein Vector (Mouse) (pPB-N-His)

PV178883 500 ng
EUR 1278

FBXW7 Protein Vector (Mouse) (pPM-C-His)

PV178885 500 ng
EUR 1278

FBXW7 Protein Vector (Mouse) (pPB-C-His)

PV178886 500 ng
EUR 1278

FBXW7 Protein Vector (Mouse) (pPB-N-His)

PV178887 500 ng
EUR 1278

FBXW7 Protein Vector (Mouse) (pPM-C-His)

PV178889 500 ng
EUR 1278

FBXW7 Protein Vector (Mouse) (pPB-C-His)

PV178890 500 ng
EUR 723.6

FBXW7 Protein Vector (Mouse) (pPB-N-His)

PV178891 500 ng
EUR 723.6

FBXW7 Protein Vector (Mouse) (pPM-C-His)

PV178893 500 ng
EUR 723.6

Fbxw7 3'UTR Luciferase Stable Cell Line

TU106466 1.0 ml Ask for price

FBXW7 3'UTR Luciferase Stable Cell Line

TU007813 1.0 ml
EUR 1825.2

ARP37443_P050 - Fbxw7 antibody - middle region (ARP37443_P050)

ARP37443_P050 100ul
EUR 389

Fbxw7 sgRNA CRISPR Lentivector (Mouse) (Target 1)

K4531702 1.0 ug DNA
EUR 184.8

Fbxw7 sgRNA CRISPR Lentivector (Mouse) (Target 2)

K4531703 1.0 ug DNA
EUR 184.8

Fbxw7 sgRNA CRISPR Lentivector (Mouse) (Target 3)

K4531704 1.0 ug DNA
EUR 184.8

FBXW7 sgRNA CRISPR Lentivector (Human) (Target 1)

K0767602 1.0 ug DNA
EUR 184.8

FBXW7 sgRNA CRISPR Lentivector (Human) (Target 2)

K0767603 1.0 ug DNA
EUR 184.8

FBXW7 sgRNA CRISPR Lentivector (Human) (Target 3)

K0767604 1.0 ug DNA
EUR 184.8

Monoclonal FBXW7 Antibody (monoclonal) (M02), Clone: 3D1

AMM03534G 0.1mg
EUR 580.8
Description: A Monoclonal antibody against Human FBXW7 (monoclonal) (M02). The antibodies are raised in mouse and are from clone 3D1. This antibody is applicable in WB and IHC, E

AAP47419-100UG - FBXW7 Peptide - C-terminal region

AAP47419-100UG 100ug
EUR 99

Lenti ORF clone of Fbxw7 (mGFP-tagged) - Mouse F-box and WD-40 domain protein 7 (Fbxw7), transcript variant 2

MR225460L4 10 µg Ask for price

Lenti ORF clone of Fbxw7 (mGFP-tagged) - Mouse F-box and WD-40 domain protein 7 (Fbxw7), transcript variant 1

MR225461L4 10 µg Ask for price

Lenti ORF clone of Fbxw7 (mGFP-tagged) - Mouse F-box and WD-40 domain protein 7 (Fbxw7), transcript variant 3

MR225462L4 10 µg Ask for price

ARP47419_P050-25UL - FBXW7 Antibody - C-terminal region

ARP47419_P050-25UL 25ul
EUR 99

OAAB19237-400UL - FBXW7 Antibody - N-terminal region

OAAB19237-400UL 400ul
EUR 389

ARP47419_P050 - FBXW7 Antibody - C-terminal region (ARP47419_P050)

ARP47419_P050 100ul
EUR 389

Lenti ORF clone of Fbxw7 (Myc-DDK-tagged) - Mouse F-box and WD-40 domain protein 7 (Fbxw7), transcript variant 2

MR225460L3 10 µg Ask for price

Lenti ORF clone of Fbxw7 (Myc-DDK-tagged) - Mouse F-box and WD-40 domain protein 7 (Fbxw7), transcript variant 1

MR225461L3 10 µg Ask for price

Lenti ORF clone of Fbxw7 (Myc-DDK-tagged) - Mouse F-box and WD-40 domain protein 7 (Fbxw7), transcript variant 3

MR225462L3 10 µg Ask for price

FBXW7 (untagged) - Homo sapiens F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase (FBXW7), transcript variant 4

SC332501 10 µg Ask for price

FBXW7 mouse monoclonal antibody, clone OTI6H1 (formerly 6H1)

TA802822 100 µl Ask for price

FBXW7 mouse monoclonal antibody, clone OTI6H1 (formerly 6H1)

TA802822S 30 µl Ask for price

FBXW7 mouse monoclonal antibody, clone OTI2G7 (formerly 2G7)

TA802834 100 µl Ask for price

FBXW7 mouse monoclonal antibody, clone OTI2G7 (formerly 2G7)

TA802834S 30 µl Ask for price

FBXW7 mouse monoclonal antibody, clone OTI6F5 (formerly 6F5)

TA802869 100 µl Ask for price

FBXW7 mouse monoclonal antibody, clone OTI6F5 (formerly 6F5)

TA802869S 30 µl Ask for price

FBXW7 mouse monoclonal antibody, clone OTI1C7 (formerly 1C7)

TA802873 100 µl Ask for price

FBXW7 mouse monoclonal antibody, clone OTI1C7 (formerly 1C7)

TA802873S 30 µl Ask for price

FBXW7 mouse monoclonal antibody, clone OTI4E7 (formerly 4E7)

TA802970 100 µl Ask for price

FBXW7 mouse monoclonal antibody, clone OTI4E7 (formerly 4E7)

TA802970S 30 µl Ask for price

FBXW7 (GFP-tagged) - Homo sapiens F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase (FBXW7), transcript variant 4

RG233368 10 µg Ask for price
METHODS
Data coming from 4 pollen monitoring stations in the Berlin and Brandenburg space in Germany and for three years (2014-2016) have been used to analyze the correlation of season definitions, birch and grass pollen counts and complete nasal symptom and mediation scores as reported by sufferers in “Patients Hay fever Diaries” (PHDs). After the identification of pollen durations on the foundation of the EACCI standards, a statistical evaluation was employed, adopted by an in depth graphical investigation.
RESULTS
The evaluation revealed that the definitions of pollen season in addition to peak pollen interval begin and finish as proposed by the EAACI are correlated to symptom hundreds for grass and birch pollen-induced allergic rhinitis reported by sufferers in PHDs.
CONCLUSIONS
Based on our evaluation, the validity of the EAACI definitions on pollen season is confirmed. Their use is advisable in future medical trials on AIT in addition to in each day routine for optimum affected person care.

Antigens

Antigens are defined as substances capable of stimulating the production of antibodies, with which they react specifically. This definition is incomplete since it is well known that antigens can induce cell-mediated immune responses. So antigens are all molecules introduced into the body that can induce an immune response; that is to say the induction of the production of specific immune effectors (humoral or cellular) and to react with these.

antigen is a category of molecules (a molecular species) defined by its antigenic specificity. And, it defines antigenic specificity as the property of a given antigen to combine with a given (usually heterogeneous) population of antibodies. A given antigen can combine with several different or identical antibodies.

Classifications

According to origin

– Xeno-antigen XENO ANTIGENS: these are the antigens present in all individuals of one or more species distinct from that to which the immunized subject belongs.
– Allo antigens (Iso antigens): these are antigens found in a group of individuals of the same species and can induce an immune response in individuals who do not have them.
– Auto antigens: these are the antigens of an individual that can induce an anti-self immune response.

Depending on whether the production of antibodies depends on T cells or not

– Thymo-dependent antigens: are those against which the production of antibodies requires the help of T lymphocytes. This category is mainly represented by proteins.
– Thymo independent antigens: are those against which the production of antibodies does not require the help of T lymphocytes; such as polysaccharides and lipopolysacharides which are characterized by the presence of repetitive epitopes.

According to the chemical nature

 Protein antigens: these are the most immunogenic antigens. There are several types:
– Natural proteins: these are the main constituents of living things. They are encoded by corresponding genes.
– Artificial proteins: these are proteins whose natural core is on which side sequences are grafted.
– Synthetic proteins.

 Polysaccharide antigens: the immunogenic power of these antigens is weak. The simple polysaccharides have repetitive antigenic determinants which can activate B lymphocytes without resorting to T lymphocytes. The antigenic determinants of these antigens are sequential and nonconformational determinants, of approximately 6 sugars.

 Lipid antigens: lipids are not immunogenic. however, after their association with proteins, they can induce an immune response. They play the role of haptens. In certain diseases we find anti phospholipid antibodies.

 Nucleic acids: the immunogenicity of these substances is controversial when all attempts at immunization fail. However, immunization with nucleic acids associated with proteins induces the production of specific antibodies.

According to physical properties (solubility)

 Soluble antigens: constitute the majority of antigens in nature (proteins, polysaccharides, etc.)
 Particulate antigens: correspond to all particles, living or inert, which can induce an immune response (bacteria, virus, cell, parasite, etc.)

Applications

  1. vaccination
  2. serotherapy
  3. in vitro diagnosis
  4. skin tests
  5. desensitization

IMMUNOGLOBULINES

Our body has a defense system (immune system) ensuring its integrity.
It defends it against exogenous aggressions (microorganisms) and monitors pathological cell proliferation. To accomplish this task, it has natural (innate, non-specific) and other adaptive (acquired or specific) control mechanisms. The latter are provided by effectors which recognize antigens in a specific way.

What are immunoglobulines?

Immunoglobulins are serum glycoproteins from mammalian interstitial fluid that are produced by B cells (membrane immunoglobulin) or by plasma cells (soluble immunoglobulin). In general, it is produced following specific antigenic stimulation. Immunoglobulins produced after antigen stimulation or those having corresponding antigens are called ANTIBODIES.

CLASSES AND SUBCLASSES OF IMMUNOGLOBULINS

In mammals, there are five classes of immunoglobulins (IgG, IgM, IgA, IgE and IgD) which differ in their Phi, the half-life, the number of constant domains and the role of the constant parts. The classes and subclasses are terminated by the types of heavy chains; each of these chains is encoded by a different gene.

1/ Immunoglobulin G (IgG)

it is a glycoprotein made up of two heavy chains (γ) and two light chains (κ or λ). It represents 70 to 75% of total immunoglobulins with a concentration of 10 to 18 g / l. She
includes four subclasses: IgG1, IgG2, IgG3 and IgG4 and which represent 66%, 23%, 7% and 4% of IgG respectively. The difference between them lies in the hinge region and in the number of disulfide bridges.
Half of these immunoglobulins are 21 days, except for IgG3 which is 7 days. Their sedimentation constant is 7 S and with a PM of 146 Kd. IgG (1,2,3) fix the complement. Only IgG1 and IgG3 which can cross the placenta. The γ chain consists of 3 constant domains and a variable. But all light chains are only formed from two domains, a constant and a variable.

2/ Immunoglobulin A (IgA)

it is a glycoprotein in two forms, a monomeric form consisting of two heavy chains (α) and two light chains (κ or λ) and represents 80% of serum IgA. The second form is predominant in secretions (milk, saliva …). It is dimeric of 385 Kd and 11 S. it contains the chain J of 15 Kd plus a secretory component of 70 Kd. IgA groups two subclasses:
IgA1 which is found, above all, in serum form and IgA2 which is found, above all, in secretory form. The concentration of serum IgA is 1 to 4.5 g / 1. They do not fix the complement and do not cross the placenta. The α chain consists of 3 constant domains and a variable.

3/ Immunoglobuline M (IgM)

it is a glycoprotein of 900 Kd and 19 S. Usually, it is pentameric and made up of 10 heavy chains (μ) and 10 light chains (κ or λ) identical. It represents 10% of serum immunoglobulins. The subunits are linked together by disulfide bridges and the chain J (junction). The μ chain contains four constant domains and one variable. The membrane IgM is monomeric containing an additional hydrophobic sequence which allows it to anchor to the cytoplasmic membrane. This molecule constitutes the specific receptor for the antigen on the B lymphocyte (BCR). It is associated with two molecules Igα (CD79a) and Igβ (C79b) which are responsible for signal transduction after antigenic stimulation.

4/ Immunoglobulin D

it is a glycoprotein consisting of two heavy chains (δ) and two light chains q (κ or λ) identical. It represents 10% of serum Ig. It exists in two forms; the serum form which is soluble and the membrane form which constitutes, with the membrane IgM, the BCRs of mature B lymphocytes. It is the most sensitive to proteolysis.
The heavy chains δ only bind to each other by a disulfide bridge. It is 184 kd, 7 S and a half-life of 3 days. The serum concentration is 0.05 to 0.4 g / l. the heavy chain has three constant domains and one variable.

5/ Immunoglobulins E

it is 190 Kd and 8S glycoprotein with a half-life of 3 days. It consists of two heavy chains (ε) and two light chains (κ or λ). Its serum concentration is 0.003 g / l. Most IgE are found to be fixed on basophils and mast cells by receptors specific to the constant part (RFCεI). It does not fix the complement and does not cross the placenta. It is a thermolabile Ig.

ANTIGENIC PROPERTIES

an immunoglobulin can induce an adaptive immune response (production of antibodies). So it has the properties of an antigen. The antibodies produced are directed against the various antigenic determinants located on the constant part or the variable part. There are three groups of antigenic determinants of light chains or heavy chains defining the isotype, allotype and idiotype.

1- Isotype: it is the properties of antigenic determinants which define the classes and subclasses of immunoglobulins of the same species. It is carried by the constant part.

2 – Allotype: it is the properties of antigenic determinants which differentiate different individuals within the same species. It is carried by the constant part.

3 – Idiotype: it is the properties of antigenic determinants which differentiate immunoglobulins of the same isotype and of same allotype in an individual. It is carried by the variable part.

ORGANIC ROLES

An immunoglobulin molecule consists of a variable part, represented by the Fab fragment which constitutes the site of attachment of the antigen to the antibody; the latter is called the PARATOPE. So the variable part is responsible for the recognition of the antigen and the reaction with it. The constant party represented by the FC plays several roles:
(1) Activation of the complement (IgG1, IgG2, lgG3).
(2) binding to receptors carried by cells derived from the hematopoietic line (cytophilia or cytotropy).
IgG have three receptors: RFCγI or CD 64, RFCγII or CD 32 and RFCγIII or CD 16. They mainly fix IgG l and IgG 3. They are expressed by monocytes, macrophages, polynuclear, NK and CTL. IgEs have two receptors: RFCε I which is expressed by mast cells and basophils and RFCεII or CD23 which is expressed by the majority of blood cells (monocyte; polynuclear, lymphocytes, platelets …).
(3) the catabolism of immunoglobulins whose speed is regulated by Fc and more precisely by CH2.
(4) certain isotypes of immunoglobulins have the property of crossing cells (trans cytosis). IgA is secreted in exocrine secretions and IgG is secreted in the interstitial fluid.

IMMUNE RESPONSE

The first contact of the antigen With the organism activates the immune cells (T and B lymphocytes) and induces a primary immune response which is characterized by:

  • The latency phase lasts several days
  • The Ig level is slightly increased and then declines rapidly
  • The isotype is IgM

The second contact induces a secondary immune response which is characterized by:

  • The latency phase is very short
  • the Ig level is very high
  • the isotype is IgG especially with also IgA and IgM

Applications

Diagnostic:
-Search for soluble or particulate antigens (invitro)
-Immuno-scintigraphy (invivo)
-Serodiagnosis
Therapeutic:
-Serotherapy
-IGIV.